Hypothyroidism and AMH in Iraqi Patients with Chronic Kidney Disease

Main Article Content

Noori M. Luaibi
http://orcid.org/0000-0002-7572-4121
Athraa K. Falhi
Ali J. Alsaedi

Abstract

This study was conducted to investigate thyroid function and Anti-Müllerian hormone (AMH) in (Chronic kidney disease) CKD patients by evaluating their levels in CKD patients, 50 patients were diagnosed to have CKD stage-5, their ages ranged between 20-50 years (25 males and 25 females) who attended the Nephrology and Transplant Center in Medical City of Baghdad- Iraq, they were recruited from April 2018 to July 2018 and were enrolled into the study. The control group consisted of 20 healthy individuals, their ages ranged between 20-48 years (10 males and 10 females). The study showed non-significant (p>0.05) increase in AMH level in CKD patients compared to the control group. On the other hand, TSH was recorded a highly significant (P<0.01) increase in CKD patients in comparison with control. While T3 and T4 levels recorded highly significant (P<0.01) decrease in CKD patients in comparison with control.


 

Article Details

How to Cite
1.
Hypothyroidism and AMH in Iraqi Patients with Chronic Kidney Disease. Baghdad Sci.J [Internet]. 2021 Mar. 30 [cited 2024 Mar. 29];18(1(Suppl.):0695. Available from: https://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3681
Section
article

How to Cite

1.
Hypothyroidism and AMH in Iraqi Patients with Chronic Kidney Disease. Baghdad Sci.J [Internet]. 2021 Mar. 30 [cited 2024 Mar. 29];18(1(Suppl.):0695. Available from: https://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3681

References

Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006 Aug; 17(8): 2275-2284.

Emanuele Di, John D, Gudny E. Vilmundur G. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med. 2007 Sep ; 4 (9): 270.

Lysaght, M J. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol, (2002); 13(1): 37-40.

Dor A, Pauly MV, Eichleay MA, Held PJ. End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ. 2007 Sep; 7(2-3): 73-111.

Edey MM. Male Sexual Dysfunction and Chronic Kidney Disease. Front. Med. 2017 Mar; 4(32): 1-10.

Shibusawa K, Saito S, Nishi K, Yamamoto T, Abe C, Kawai T. Effects of the thyrotrophin releasing principle (TRF) after the section of the pituitary stalk. Endocrinol Jpn .1956 ; 3(3): 151-157.

Schweizer U, Weitzel JM, Schomburg L. Think globally: act locally. New insights into the local regulation of thyroid hormone availability challenge long accepted dogmas. Mol Cell Endocrinol. 2008; 289(1-2): 1-28.

Ritchie M, Yeap BB. Thyroid hormone: Influences on mood and cognition in adults. Maturitas. 2015 Jun; 81(2): 266-275.

Iglesias P, Carrero JJ, Díez JJ. Gonadal dysfunction men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol. 2012 Feb; 25(1): 31-42.

Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-mullerian hormone and antral follicle count as biomarkers of ovarian response. Hum. Reprod Update. 2015 Nov-Dec; 21(6): 698-710.

Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-mullerian hormone in women. Hum. Reprod Update. 2014 May-Jun; 20(3): 370-385.

Lindhardt JM, Hagen CP, Johannsen TH, Main KM, Picard JY. AntiMullerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development. Int J Endocrinol. 2013 Dec; 2013: 1-10.

Goulis DG, Iliadou PK, Tsametis C, Gerou S, Tarlatzis BC, Bontis IN, Papadimas et al. Serum anti-Mullerian hormone levels differentiate control from subfertile men but not men with different causes of subfertility. Gynecol Endocrinol. 2008 Mar; 24(3):158-160.

Sikora-Grabkaa E, Adamczaka M, Kuczeraa P, Szotowskaa M, Madejb P, Wieceka A. Serum Anti-Müllerian Hormone Concentration in Young Women with Chronic Kidney Disease on Hemodialysis, and After Successful Kidney Transplantation. Kidney Blood Press Res. 2016 Aug; 2016(41):552-560.

Stoumpos S, Lees J, Welsh P, Hund M, Geddes C, Nelson S, et al. The utility of anti-Müllerian hormone in women with chronic kidney disease, on haemodialysis and after kidney transplantation. Reprod Biomed Online. 2018 Feb; 36 (2):219-226.

Eckersten D, Giwercman A, Bruun L, Christensson A. Anti-Mullerian hormone, a Sertoli cell-derived marker, is decreased in plasma of male patients in all stages of chronic kidney disease. Androl. 2015 Oct; 3(6): 1160-1164.

Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol, 2012 Jul; 23 (7): 1258-1270.

Eckersten D, Giwercman A, Christensson A. Male patients with terminal renal failure exhibit low serum levels of antimüllerian hormone. Asian J Androl. 2015b Jan-Feb; 17(1): 149-153

Singh Sm, Verma A, Aryal A, Thapa S, Khakurel S, Shrestha K. Thyroid hormone profile in patients with chronic kidney disease: a single centre study .J Nepal Health Res Counc. 2016 Sep; 14(34): 197-201.

Keerthana BL, Kumar TA. Study of Thyroid and Lipid Profile in Chronic Kidney Disease. Int J Med Health Res. 2016 Mar 2(3): 6-9

Yilmaz MI, Sonmez A, Karaman M, Ay SA, Saglam M, Yaman H. Low triiodothyronine alters flow mediated vasodilatation in advanced nondiabetic kidney disease. Am J Nephrol. 2011Jan; 33(1):25-32.

Thalquotra M, Pandey R, Singh J, Agrawal BK, Sodhi KS. Evaluation of thyroid profile in patients with chronic kidney disease. J Pharm Biomed Sci. 2014 ; 4(2):143-147.

Song SH, Kwak IS, Lee DW, Kang YH, Seong EY, Park JS. The prevalence of low triiodothyronine according to the stage of chronic kidney disease in subjects with a normal thyroid-stimulating hormone. Nephrol Dial Transplant. 2009 May; 24(5): 1534-1538.

Rajeev G, Chickballapur RW, Vijayalakshmi R, Swathi M, Kumar S. Evaluation of thyroid hormone levels in chronic kidney disease patients. Saudi J Kidney Dis Transpl. 2015 Jan; 26(1): 90-93.

Kannan A, Sriramakrishnan V, Kannan B, Anandan H. Thyroid Function Abnormalities in Patients with Chronic Kidney Disease - A Prospective Study. Int J Sci Study. 2017 Jul; 5(4): 68-72.

Rajagopalan B, Dolia PB, Arumalla VK. Renal function markers and thyroid hormone status in undialyzed chronic kidney disease. Al Ameen J Med Sci. 2013 Jan; 6(1): 70-74.

Kuczera P, Adamczak M, Wiecek A. Endocrine abnormalities in patients with chronic kidney diseases. Sec. of Med. Sci.2015 (36); 2: 109-118.

Khaled MD, Faiz AT, Abdelgader A, Bioprabhu S. Thyroid Hormones and Lipid Profile Changes during Hemodialysis in CKD Cases of Libya. J Dent Med Sci. 2015; 14(11): 73-81.

Swaminathan K, Rajesh S, Avudaiappan S. A Study of Thyroid Function Abnormalities in Patients with Chronic Kidney Disease. J Dent Med Sci. 2016; 15(8): 7-15.

Kuroda K, Uchida T, Nagai S. Elevated serum thyroid-stimulating hormone is associated with decreased anti-Müllerian hormone in infertile women of reproductive age. J Assist Reprod Genet. 2014 Feb; 32(2): 243-247.

Zhang C, Wang X, Wang Z, Niu W, Zhu B, Xia G. Effect of different culture systems and 3, 5, 3 ′-triiodothyronine/follicle-stimulating hormone on preantral follicle development in mice. PLoS ONE. 2013 Apr; 8(4): 1-7.

Fedail JS, Zheng K, Wei Q, Kong L, Shi F. Roles of thyroid hormones in follicular development in the ovary of neonatal and immature rats. Endocrine. 2014 Aug: 46 (3):594-604.

Similar Articles

You may also start an advanced similarity search for this article.